Merz North America, Inc.

Quick facts

Marketed products

• NAFT500 (adult) · Aesthetics / Dermatology
  NAFT500 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.
• NAFT500 (pediatric) · Dermatology / Infectious Disease
  NAFT500 is a naftifine hydrochloride topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase.
• NAFT600 (adult) · Aesthetics; Neurology
  NAFT600 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.
• NAFT600 (pediatric) · Dermatology
  NAFT600 is a botulinum toxin product used to reduce muscle contractions and treat movement disorders in pediatric patients.
• Naftin Cream

Phase 3 pipeline

• NAFT-500 · Dermatology
  NAFT-500 is a naftifine derivative designed to modulate skin barrier function and reduce inflammation in dermatological conditions.
• NAFT-600 ( naftin 2 % gel ) · Dermatology
  Naftin is an allylamine antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.
• Naftin 1% Cream · Dermatology
  Naftin (naftifine) is a topical antifungal that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.
• Placebo 2-weeks
  Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.
• Placebo 4-weeks
  Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Merz North America, Inc. portfolio CI brief
• Merz North America, Inc. pipeline updates RSS